BSN CAPITAL PARTNERS Ltd Lowers Holdings in Boston Scientific Corporation $BSX

Key Points

• BSN Capital Partners cut its Boston Scientific stake by 74.2% in the first quarter, selling 371,000 shares and retaining 129,000 shares worth approximately $8.1 million.
• Boston Scientific beat second-quarter estimates with adjusted EPS of $0.86 and revenue of $5.44 billion, up 7.5% year over year. However, the company lowered its full-year outlook due to weakness in its electrophysiology and WATCHMAN businesses.
• Analysts remain broadly positive, with 24 Buy ratings and an average price target of $71.62, despite recent target cuts and risks from a product recall, restructuring costs and the stock’s decline to about $46.75.

BSN CAPITAL PARTNERS Ltd cut its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 74.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,000 shares of the medical equipment provider's stock after selling 371,000 shares during the quarter. Boston Scientific comprises approximately 0.4% of BSN CAPITAL PARTNERS Ltd's portfolio, making the stock its 22nd biggest position. BSN CAPITAL PARTNERS Ltd's holdings in Boston Scientific were worth $8,095,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Outfitters Financial LLC raised its holdings in Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider's stock worth $2,291,000 after buying an additional 110 shares during the last quarter. Natural Investments LLC grew its holdings in shares of Boston Scientific by 2.9% during the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider's stock valued at $384,000 after buying an additional 112 shares during the last quarter. Patton Fund Management Inc. increased its position in shares of Boston Scientific by 5.5% during the fourth quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider's stock valued at $217,000 after acquiring an additional 118 shares in the last quarter. Bridgewater Advisors Inc. increased its position in shares of Boston Scientific by 1.2% during the fourth quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider's stock valued at $921,000 after acquiring an additional 123 shares in the last quarter. Finally, CYBER HORNET ETFs LLC raised its holdings in Boston Scientific by 3.4% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider's stock worth $391,000 after acquiring an additional 132 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

BSX has been the topic of a number of research analyst reports. Raymond James Financial reaffirmed an "outperform" rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday. Mizuho decreased their target price on Boston Scientific from $90.00 to $70.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Needham & Company LLC lowered their target price on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a research note on Wednesday, July 8th. Bank of America lowered their target price on shares of Boston Scientific from $105.00 to $68.00 and set a "buy" rating on the stock in a research note on Monday, May 18th. Finally, Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a research note on Wednesday. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and an average target price of $71.62.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $46.75 on Monday. The company has a market capitalization of $69.48 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 1.02 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The stock's 50-day simple moving average is $46.13 and its 200-day simple moving average is $62.02. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The firm had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same quarter last year, the business posted $0.75 earnings per share. The company's revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a stock repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

Insiders Place Their Bets

In other news, Director Cheryl Pegus purchased 1,770 shares of the company's stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 9,800 shares of company stock worth $554,012 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.